MGLL and breast carcinoma: To characterize the potential activity of MAGL inhibitor AM9928 on the inflammatory responses in breast cancer, we used TNBC cells, the MDA-MB-231 and MDA-MB-BrM2 cells, as compared to the immortalized normal breast epithelial MCF-10A cells.